Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bolaget.

Datum Källa Rubrik Typ Alternativ
2022-10-14 Asarina Pharma Asarina Pharma: Full rekrytering och sista patienten randomiserad i den viktiga studien om Tourettes syndrom Pressreleaser Ladda ner | Visa Stäng
2022-10-14 Asarina Pharma Asarina Pharma: Patient recruitment completed in landmark Tourette syndrome study Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Omfattande ny preklinisk studie ökar säkerheten av Asarina Pharmas resultat om en viktig stressmekanism involverad i Tourettes syndrom och OCD Pressreleaser Ladda ner | Visa Stäng
2022-10-06 Asarina Pharma Extensive new preclinical study significantly increases the Translatability of Asarina Pharma's findings on key stress mechanism implicated in Tourette Syndrome and OCD Pressreleaser Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Q2 2022 Report released Rapporter Ladda ner | Visa Stäng
2022-08-25 Asarina Pharma Asarina Pharma AB (publ) Rapport för andra kvartalet 2022 släppt Rapporter Ladda ner | Visa Stäng
2022-06-23 Asarina Pharma Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen Pressreleaser Ladda ner | Visa Stäng
2022-06-23 Asarina Pharma Asarina Pharma genomför en riktad nyemission av aktier efter begäran om lånkonvertering från Östersjöstiftelsen Pressreleaser Ladda ner | Visa Stäng
2022-05-25 Asarina Pharma Asarina Pharma AB (publ) Rapport för första kvartalet 2022 släppt Rapporter Ladda ner | Visa Stäng
2022-05-25 Asarina Pharma Asarina Pharma AB (publ) Q1 2022 Report released Rapporter Ladda ner | Visa Stäng
2022-05-04 Asarina Pharma Kommuniké från årsstämma i Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-05-04 Asarina Pharma Bulletin from the Annual General Meeting of Asarina Pharma AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-06 Asarina Pharma Asarina Pharma: ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 6 Apr 2022 | Asarina Pharma

Asarina Pharma: ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED

FINANCIAL HIGHLIGHTS

  • Total operating costs were reduced by more than 50% to SEK 38.3 million.
  • R&D costs dropped to SEK 29.9 millionfrom SEK 63.7 million in 2020.The Company received a convertible loan of SEK 5.3 million from Östersjöstiftelsen. We expect the cash position of SEK 21.7 million at year-end to be sufficient to finance the phase IIa Tourette study.

R&D HIGHLIGHTS

FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that Sepranolone suppresses tics in Tourette Syndrome with no observable side-effects.

JUNE 8: The US Patent and Trademark Office grants a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling.

JUNE 23: Topline results from Asarina’s phase IIa study of Sepranolone for menstrual migraine find that a statistically significant difference compared to placebo was not obtained in the study’s primary and secondary endpoints.

SEPTEMBER 28: A post hoc analysis of Sepranolone for PMDD (Premenstrual Dysphoric Disorder) finds that Sepranolone in a 10 mg dose demonstrated a significant treatment effect compared to placebo, when examined in an extended 9-day analysis of symptom reduction. (The original study targeted a 5-day treatment period).

DECEMBER 22: Administrative approval of the two study sites for our phase IIa clinical study in Tourette syndrome was obtained following a five-month delay due to an administrative backlog in Copenhagen’s Region Hovedstaden city government.

To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/

2022-04-06 Asarina Pharma Asarina Pharma: ASARINA PHARMA AB (publ) ÅRSREDOVISNING 2021 PUBLICERAD Pressreleaser Ladda ner | Visa Stäng
2022-04-05 Asarina Pharma Asarina Pharma: NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ) Pressreleaser Ladda ner | Visa Stäng
2022-04-05 Asarina Pharma Asarina Pharma: KALLELSE TILL ÅRSSTÄMMA i ASARINA PHARMA AB (publ) Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

25 Feb 2023 | Kvartalsrapport 2022-Q3